Joint Loss of PAX2 and PTEN Expression in Endometrial Precancers and Cancer
- 28 July 2010
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 70 (15), 6225-6232
- https://doi.org/10.1158/0008-5472.can-10-0149
Abstract
Latent endometrial carcinoma precancers are normal-appearing endometrial glands with sporadic loss of tumor suppressor gene function such as PTEN. Progression to carcinoma is inefficient and requires additional genetic damage that creates a histologic precursor lesion called endometrial intraepithelial neoplasia (EIN). In this study, we examined loss of PAX2 expression, a gene required for embryonic uterine development, during endometrial carcinogenesis. Normal proliferative, EIN, and malignant (endometrial adenocarcinoma) endometrial tissues were immunostained for PTEN and PAX2. Proliferative samples with loss of protein in at least one gland were scored as latent precancers. EIN and cancer lesions were scored by the majority pattern. Overall prevalence and topography of joint PAX2-PTEN expression loss was examined. The prevalence of PAX2 protein loss in the sequence of normal to precancer to cancer was 36%, 71%, and 77%, respectively, and for PTEN, it was 49%, 44%, and 68%, respectively. The normal endometrial prevalence of PAX2- or PTEN-deficient latent precancers was unaffected by biopsy indication, but increased significantly with age. Coincident loss of PAX2 and PTEN expression in an individual normal endometrium was seen in 21% of patients, but usually involved different glands. Coincident loss was more common in precancers (31%) and carcinoma (55%), in which case, both markers were protein null in an overlapping clonal distribution. PAX2 and PTEN protein loss occurs independently and accumulates with increasing age in latent precancers of normal premenopausal endometrium. Loss of function of both genes in an overlapping distribution characterizes the clinical emergence of a premalignant lesion which is carried forward to carcinoma. Cancer Res; 70(15); 6225–32. ©2010 AACR.Keywords
Other Versions
This publication has 28 references indexed in Scilit:
- Involution of latent endometrial precancers by hormonal and nonhormonal mechanismsCancer, 2009
- Regulation of ERBB2 by oestrogen receptor–PAX2 determines response to tamoxifenNature, 2008
- Early aberrant insulin‐like growth factor signaling in the progression to endometrial carcinoma is augmented by tamoxifenInternational Journal of Cancer, 2008
- PTEN Expression in Endometrial Biopsies as a Marker of Progression to Endometrial CarcinomaCancer Research, 2008
- Benign Endometrial Hyperplasia Sequence and Endometrial Intraepithelial NeoplasiaInternational Journal of Gynecological Pathology, 2007
- Regression of Latent Endometrial Precancers by Progestin Infiltrated Intrauterine DeviceCancer Research, 2006
- Global Expression Changes of Constitutive and Hormonally Regulated Genes during Endometrial Neoplastic TransformationGynecologic Oncology, 2001
- PTEN, a Protean Tumor SuppressorThe American Journal of Pathology, 2001
- Primary prevention of gynecologic cancersAmerican Journal of Obstetrics and Gynecology, 1995
- The epidemiology of endometrial cancerGynecologic Oncology, 1991